NewLimit, a South San Francisco biotech co-founded by CEO Jacob Kimmel, Coinbase's Brian Armstrong and investor Blake Byers, has raised $682 million to develop anti-aging drugs based on epigenetic reprogramming. The company has been named an Endpoints 11 2026 winner. Backers include Kleiner Perkins, Founders Fund, Dimension Capital, Eli Lilly Ventures and Thrive Capital. The funding is unusually large for a private firm working on aging biology, a field that has yet to produce an approved drug. NewLimit's approach involves partially resetting gene regulation patterns in cells to restore youthful function without triggering cancer risk. The company must eventually select a specific disease indication for clinical trials, as no regulatory pathway currently treats aging itself. The capital provides runway to develop candidates before committing to human studies.

NewLimit raises $435M in Series C funding. June 3, 2026 NewLimit, a San Francisco, California-based developer of cell reprogramming and epigenetic longevity medicines, raised $435m in Series C funding. The round was led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman, Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. The company intends to use the funds to advance its portfolio of age-reprogramming therapies, expand its computational biology teams, and transition its lead liver-cell program into its first human clinical studies. Led by Co-Founders Brian Armstrong and Blake Byers, alongside CEO and President Jacob Kimmel, NewLimit develops an AI-driven genomics platform designed to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated its development timeline to initiate its first investigator-led human trials in late 2027. Don't just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week - in our structured Master Database (XML) + Weekly Intelligence PDF. [Access FinSMEs Intelligence Hub] 03/06/2026

NewLimit raises USD 435m Series C to advance aging reprogramming medicine toward human trials. June 2, 2026 South San Francisco-based NewLimit, a biotechnology company focused on longevity medicine, has closed a USD 435 million Series C funding round as it prepares to bring its first aging reprogramming therapy into human clinical trials. Founders Fund led the round, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital. Returning investors included Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others. The company said it plans to use the capital to advance its lead program - a prototype medicine designed to reverse cell age in old human liver cells - into first-in-human trials, which the company indicated are expected to begin next year. According to NewLimit's operating plan, the lead program is based on lipid nanoparticle-delivered RNA medicines designed to transiently express combinations of transcription factors in aged liver cells. The initial focus is alcohol-related liver disease, a setting where aging hepatocytes lose regenerative capacity and become increasingly susceptible to injury. The company has reported identifying multiple reprogramming payloads that restore youthful function in preclinical liver models with one of those selected for further development. NewLimit argues that its work represents one of the most advanced efforts in the emerging field of partial cellular reprogramming, which remains largely preclinical despite substantial investor interest. If the company proceeds on its stated timeline, it would represent one of the first direct tests of an epigenetic reprogramming approach in human subjects. The financing ranks among the largest private biotech rounds completed this year and underscores continued investor enthusiasm for longevity-focused drug development. The scale of the Series C reflects broader momentum in longevity-focused biotech, where investors have shown increasing appetite for programs targeting the biology of aging itself rather than individual age-related diseases. Eli Lilly Ventures' continued participation is notable, given Lilly's expanding interest in metabolic and age-related biology following the commercial success of its GLP-1 franchise.